Abstract: Ciclesonide is a novel inhaled corticosteroid used in the continuous treatment of mild-to-severe asthma. Its formulation and mechanism of action yield a low oral and systemic bioavailability, and high pulmonary deposition. In multiple clinical trials, ciclesonide is at least as effective as either fl uticasone propionate or budesonide at symptom control, while in many cases having improved safety outcomes and tolerability. The improved safety and comparable effi cacy profi les of ciclesonide demonstrated in current studies could potentially yield a treatment option that may lead to improved adherence and outcome.
Introduction
Asthma poses a signifi cant burden to society in terms of morbidity, mortality, quality of life, and healthcare costs. [1] [2] [3] Among children, asthma rates in the United States are currently at record highs, with a nationwide prevalence of approximately 9% of children aged 1 to 17 years. 3 Its burden on the economy is estimated at between US$4 to 6 billion annually, considering healthcare costs and lost work days for caregivers and patients alike. 4 Inhaled corticosteroids (ICS) are recommended as fi rst-line therapy for the treatment of asthma, 5, 6 and can improve both asthma symptomatology and the markers of airway infl ammation. [7] [8] [9] However, despite being demonstrated as an effi cacious controller therapy, concerns remain regarding the potential for adverse side effects associated with chronic ICS treatment. Specifi cally, some ICS molecules have been demonstrated to cause reductions in growth velocity [9] [10] [11] and bone mineral density, 12, 13 HPA-axis suppression, 14, 15 and oral candidiasis. 16, 17 Ciclesonide (Alvesco ® ; Sepracor, Inc., Nycomed, Inc.) is a novel, new corticosteroid developed for the treatment of mild to severe persistent asthma. It is delivered by metered-dose inhaler (MDI) once daily or twice daily (dosing depends on country). This review will focus on the safety and effi cacy profi le of ciclesonide, as well as to establish its mechanism of action.
Mechanism of action
Ciclesonide ([R]-11β, 16α, 17, 21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde 21-isobutyrate; CIC) is inhaled into the lungs via hydrofl uoroalkane-MDI (HFA-MDI), where it is converted by local esterases to its active metabolite, desisobutyryl-ciclesonide (des-CIC, Figure 1 ). Relative to dexamethasone (100), CIC has a low glucocorticoid receptor binding affi nity of 12, while des-CIC has a signifi cantly higher binding affi nity of 1212. 18, 19 Studies demonstrate no conversion of R-CIC or des-CIC to the S-epimer in vivo, which has different physicochemical properties, and a markedly lower receptor affi nity. 20 Pharmacokinetic profi les of des-CIC were similar in comparative healthy and asthma patients, likely indicating that bronchial narrowing and airway infl ammation do not affect the distribution of CIC and its subsequent activation to des-CIC in the lungs. 21 An additional study also demonstrated equivalent PK/PD profi les of CIC-HFA when administered with and without a spacer. 22 In vitro data indicate metabolism of des-CIC was different in precision-cut human lung and liver tissue slices. 23 After 24 hours incubation with [
14 C]-CIC, 7.2 times more radioactivity was present in the lung tissue, as compared with the liver. Furthermore, in the lung tissue [ 14 C]-CIC was converted to des-CIC and subsequently conjugated with fatty acid metabolites, a reversible process which increases lipophilicity of des-CIC and may result in prolonged drug retention and anti-infl ammatory activity in the lung (Figure 2) . 23, 24 Alternatively, [ 14 C]-CIC was catabolically inactivated in liver tissue into at least 5 different polar compounds, with dihydroxylated des-CIC being the major metabolite. 23 Additionally, other fi ndings demonstrated that orally and intravenous-administered [
14 C]-CIC resulted in a negligible serum concentration of des-CIC and no accumulation in red blood cells, indicating a low absorption and almost complete fi rst-pass metabolism (systemic bioavailability of des-CIC Ͻ 1%). 25 The demonstrated mean lung deposition of CIC is 52%. 26 The internal diameter of the smallest airways in adults are typically ∼2 μm, thus, it can be inferred that smaller ICS particles lead to greater pulmonary deposition and more even distribution throughout the lungs (Table 1) . Accordingly, the HFA-MDI formulation of CIC contains a majority of ICS particles which range between 1.1 and 2.1 μm. 27, 28 This particle size is likely related to the high observed pulmonary deposition of CIC. 28 Furthermore, uptake of CIC, budesonide (BUD), and fl uticasone propionate (FP) in human alveolar type II epithelial cells (A549) was measured, and at all incubation timepoints, intracellular concentration of CIC was higher than that of BUD and FP. 29 This indicates a more rapid uptake of CIC molecules into target tissue, and at a higher concentration. Additionally, separate in vitro data indicate intracellular concentration of des-CIC in A549 cells to be maintained for Ͼ20 hours.
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Effi cacy
Placebo-controlled
The therapeutic action of ciclesonide is achieved after the inhaled parent compound (CIC) is cleaved by esterases in the lungs to its active metabolite (des-CIC), a corticosteroid with high receptor affi nity and anti-infl ammatory activity. 18, 19, 30 In a randomized, double-blind trial, early (EAR) and late (LAR) phase allergen-induced asthmatic reactions were signifi cantly inhibited (p Ͻ 0.05) by treatment with CIC, versus placebo (as evaluated by decrease in FEV 1 following allergen challenge). 31 These anti-imfl ammatory properties were also exhibited in vitro, as CIC attenuated EAR/LAR, infi ltration of infl ammatory cells into bronchoalveolar lumen, and airway hyperresponsiveness in sensitized Brown Norway rats. 32 These effects were observed in a dose-dependent manner.
These anti-infl ammatory properties have been noted in patients with mild, persistent asthma, treated with CIC 160 μg (all doses noted in this review are ex-actuator) once-daily over a period of 4 weeks. 33 Measurements were made before and after treatment in this double-blind study for adenosine monophosphate (AMP) bronchial challenge, and exhaled nitric oxide (eNO). Mean AMP challenge PC 20 following ciclesonide treatment was signifi cantly increased (p Ͻ 0.001) compared to placebo, and decreases in eNO (ppb) and induced sputum eosinophil cell counts were also noted. 33 Additionally, Bateman et al 34 demonstrated the effectiveness of CIC 320 μg and 640 μg in reducing oral corticosteroid use in adults with severe, persistent asthma, versus placebo. Ciclesonide for asthma
Three double-blind studies demonstrated that treatment with CIC improves symptom control in patients who were previously treated with another ICS. O'Connor, et al 35 demonstrated signifi cant improvement in FEV 1 in moderate-to-severe asthmatics treated with either CIC 800 μg or 1600 μg daily, compared to placebo (12-week treatment, pretreatment with 800-2000 μg/day BDP). A similarly designed study by Langdon et al 36 noted improvements in baseline FEV 1 and morning PEF in subjects treated with CIC over a period of 12 weeks, but at more clinically-relevant doses (CIC 80 μg, 320 μg daily, versus placebo). Subjects were also previously treated with lower, constant doses of BDP or its equivalent (400-800 μg daily) for at least 4 weeks prior to randomization. Asthma control in previously treated subjects was maintained by CIC 160 μg or 640 μg once daily in another study by Chapman. 37 In a large, double-blind, 12-week study (n = 1031), Gelfand 38 studied the effect of multiple strength doses of CIC (40 μg, 80 μg, or 160 μg) on children aged 4 to 11 with mild to severe persistent asthma. Following run-in, subjects were randomized to one of three once-daily CIC treatments, or placebo. All CIC doses were associated with signifi cant increases in FEV 1 compared to placebo at study endpoint (CIC 40 μg, 11.91; CIC 80 μg, 13.58; CIC 160 μg, 14.17). Reductions in rescue medication use within study treatment cohorts were also reported.
Comparative studies
Once-daily dosing of CIC (which is approved in some, but not all countries) is a signifi cant distinction between it and other common ICS for treatment of asthma, such as BUD and FP. Currently, there have not been any comparative effi cacy trials between CIC and mometasone furoate, another commonly used ICS which is approved for once-daily dosing; future studies should directly compare effi cacy of these two agents. CIC has demonstrated effi cacy with a single daily dose, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] as well as when administered either in the morning or evening. 39 The effectiveness of a single daily dose could lead to improved compliance and symptom control in patients using CIC as asthma control therapy.
CIC comparative effi cacy trials are summarized in Table 2 . Ukena 43 demonstrated CIC 320 μg once daily to be superior to BUD 200 μg twice-daily in increasing FEV 1 from baseline (416 mL in CIC versus 321 mL in BUD; p = 0.019, 95% CI). While improvements were seen in FVC for both cohorts, a signifi cantly larger difference was seen in CIC-treated subjects. Additionally, significant improvement versus baseline in morning PEF was seen after Day 2 in the CIC cohort (p = 0.039 versus baseline) and Day 7 in the BUD cohort (p = 0.047 versus baseline), indicating a more rapid onset of action for CIC.
However, these fi ndings appear to be an outlier, as the majority of trials have found CIC at least as effective as BUD (Turbuhaler ® /DPI) in controlling asthma, in varying subject populations and disease severities.
44-48 FEV 1 improvement was noted in these studies with both BUD and CIC, and no signifi cant between-group differences were noted. Pediatric Asthma Quality of Life Questionnaire (PAQLQ) and Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ) scores were similarly improved Schaffner and Skoner over a 12-week study comparing CIC 160 μg once daily to BUD 400 μg once daily. 47 Some modest benefi t was seen for CIC, with Boulet 45 fi nding a greater percentage of symptom-free days for CIC (43%) than BUD (34%; p = 0.0288), but overall, both ICS seem to be comparably effi cacious. Similarly, comparative studies between CIC and FP show clear non-inferiority of CIC. [40] [41] [42] [49] [50] [51] No difference in comparative effi cacy was observed when comparing CIC to both FP-DPI 49 and FP-MDI. [40] [41] [42] 50, 51 FP and CIC were equally effective at maintaining asthma control in subjects who were on continuous ICS therapy prior to randomization.
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Safety and tolerability Oral candidiasis
Considering CIC is relatively inactive, and is converted to active des-CIC in the lungs versus some conversion in the oral cavity, this profi le would suggest a lower oropharyngeal deposition and frequency of side effects (ie, candidiasis). Indeed, comparative studies indicate low deposition and activated des-CIC within the oropharynx. Two similarly designed studies compared CIC to FP 52 and BUD 53 , using mouthwash solutions containing 50% ethanol at 5 time points (immediate, 15, 30, 45, and 60 minutes after inhalation) to compare deposition. The sum of CIC and des-CIC molar AUCs 0-60 min was 53% (95% CI: 40%-69%) of FP deposition 52 and 47% of the BUD deposition. 53 Furthermore, oral deposition of des-CIC was less than 10% that of FP and BUD.
Incidence of candidiasis from continuous ICS treatment is a concern, and a common reason for poor adherence, and in some cases, not beginning an asthma patient on an ICS treatment regimen. 16 For example, in one of the aforementioned effi cacy studies, 9 cases of candidiasis were noted (over a 12-week treatment period) among subjects receiving FP 200 μg twice-daily, compared to no reported cases in subjects treated with CIC 320 once-daily. 49 Likewise, Gelfand 38 found the incidence of oral candidiasis and pharyngitis over a 12-week treatment period with CIC 40 μg, 80 μg, and 160 μg to be not signifi cantly different from placebo. This fi nding is consistent with that of Pearlman, 54 who found incidences of oropharyngeal side effects similar to placebo in patients treated with CIC 80 μg, 160 μg, or 320 μg over the same duration.
HPA-axis function
Concerns of ICS acting as endogenous glucocorticoids, thereby suppressing the HPA-axis, have resulted in reluctance of some physicians to prescribe such a treatment continuously. CIC has high protein binding and high systemic clearance, a profi le that would seem to minimize interference with normal HPA-axis function. In one double-blind, randomized, crossover trial, Agertoft 55 studied children aged 6 to 12 years who were given placebo, CIC 40 μg, 80 μg, or 160 μg once daily during four 2-week treatment periods, followed by 2-week washouts. Analysis of 12 hours urinary cortisol at the end of each treatment period yielded no signifi cant betweengroup differences or dose-response effects. This is of interest because these subjects were given clinically relevant doses of CIC for their age and disease severity.
Vermeulen et al 48 found that over 12 weeks of treatment in children, CIC 320 μg once-daily was not associated with a signifi cant decrease in 24 urinary free cortisol (Δ = +1.05; nmol/mmol), while BUD 800 μg once daily was (Δ = −2.63). This between-group difference was signifi cant (p = 0.003). Adult patients (n = 60, Ն18 years) in a separate study were randomized to receive CIC 320 μg or 640 μg twice daily, FP 440 μg or 880 μg twice daily (CFC-MDI), or placebo. Neither CIC nor FP treatment was associated with a signifi cant change in mean serum cortisol AUC 0-24 h at these clinically relevant doses. 56 Alternatively, a study by Lipworth et al using the same comparative doses of FP and CIC, found evidence of adrenal suppression by FP, using cosyntropinstimulated peak serum cortisol levels to analyze HPA-axis function. 57 Noteworthy is that this pattern of adrenal safety continued even when CIC was administered in doses higher than would normally be used in clinical practice. Derom et al 58 concluded that doses as high as CIC 640 μg twice daily had no signifi cant effect on mean urinary cortisol levels (AUC 0-24 h ), while FP 440 μg and 880 μg twice daily suppressed them by 29% (95% CI, 15-41), compared with placebo. Decreases in PC 20 hyperresponsiveness were similar in all cohorts. 58 In the previously mentioned study by Szefl er, 56 serum and urinary cortisol suppression was associated with high-dose FP 2000 μg daily, but not with CIC 1600 μg daily. 56 Again, airway outcomes (PC 20 hyperresponsiveness, exhaled nitric oxide) were improved with both treatments.
Growth effects
The effects of continuous CIC treatment on childhood growth velocity have been studied. Knemometry, though not a predictor of long-term growth velocity or fi nal adult height, is an extremely sensitive measure of short-term changes in lower-leg growth. This method was utilized by Agertoft 55 to determine if 2-week treatment with CIC 40 μg, 80 μg, and 160 μg once daily resulted in any short-term changes in growth velocity. Lower leg growth rates for CIC were not signifi cantly different from placebo, and no dose-response effects were noted (placebo: 0.412 mm/week; CIC 40: 0.425 mm/week; CIC 80: 0.397 mm/week; CIC 160: 0.370 mm/week).
To date, the only long-term assessment of growth velocity in children treated with CIC was completed by Skoner et al 59 where height was assessed by stadiometry. Children (n = 661) aged 5 to 8½ years were randomized to receive placebo, CIC 40 μg, or CIC 160 μg once daily, for a treatment period of 1 year. Mean differences in yearly height from placebo (5.75 cm/year) were nonsignifi cant (−0.02 cm/year for CIC 40 and −0.15 cm/year for CIC 160), illustrating the noninferiority of CIC for growth velocity, when compared to placebo (Figure 3) . 59 Ideally, a study similar to that of Agertoft and Pedersen, 60 which determined children treated with BUD eventually reached normal adult height despite some initial reduction in growth velocity, should be performed with CIC. Ciclesonide for asthma
Conclusion
From the evidence currently available, CIC appears to be a novel, safe, and effi cacious ICS for use in the continuous treatment of asthma. The low oral bioavailability can likely be attributed to the low affi nity of CIC to glucocorticoid receptors, as compared to its active metabolite, des-CIC, which is activated in the lungs. des-CIC is highly lipid conjugated in the lungs, allowing for greater retention in target tissues, and clinically, once-daily dosing (in at least some patients). While these pharmacokinetic properties result in an effi cacious ICS, they directly contribute to the noticeably enhanced safety profi le of CIC, especially in comparison with other ICS molecules, such as BUD and FP. High protein binding and the aforementioned receptor affi nity of CIC result in low systemic bioavailability, and potentially explain the low occurrence of adverse events such as candidiasis, adrenal suppression, and growth velocity disturbance.
Comparative studies indicate the effectiveness of CIC to be similar to that of FP and BUD, but with an improved safety profi le, indicating the potential of this alternative treatment option in patients concerned about the risks of continuous ICS treatment. Minimizing risk of treatment while maintaining effi cacy is a top clinical priority to improve treatment adherence and gain optimal outcome of therapy.
